Monitor for XTX501 IND submission in mid-2026 and potential additional AbbVie milestones. The extended cash runway into 2028 reduces near-term financing risk, but the company remains pre-revenue from product sales. Watch for Series C warrant exercise in H2 2026 which could add $36.2M in proceeds.
Price Chart
Executive Summary
Xilio Therapeutics reported Q1 2026 collaboration and license revenue of $12.6M (up from $2.9M YoY) and a net loss of $9.5M (improved from a $13.3M loss in Q1 2025). The company extended its cash runway into early 2028 and achieved a $6.0M development milestone under its AbbVie collaboration. Pipeline progress remains on track with XTX501 IND submission planned for mid-2026.
Key Financial Metrics
Key Facts
- Collaboration and license revenue of $12.6M for Q1 2026, up from $2.9M in Q1 2025
- Net loss of $9.5M for Q1 2026, improved from $13.3M net loss in Q1 2025
- Cash and cash equivalents of $150.3M as of March 31, 2026, up from $137.5M at year-end 2025
- Cash runway extended into early 2028
- Achieved $6.0M development milestone under AbbVie collaboration in Q2 2026
- XTX501 IND submission on track for mid-2026 with Phase 1 initiation in H2 2026
- Presented preclinical data for XTX601 (CLDN18.2 TCE) at AACR in April 2026
- Up to $31.0M in additional near-term milestones and option extension fees possible from AbbVie through H1 2027
- Up to $36.2M in additional gross proceeds possible in H2 2026 if all Series C warrants exercised
Financial Impact
Revenue increased $9.7M YoY to $12.6M; net loss improved by $3.8M YoY to $9.5M; cash position increased $12.8M from year-end 2025
Risk Factors
- Pre-revenue clinical-stage biotech with no approved products
- Pipeline execution risk for XTX501 IND and Phase 1 initiation
- Dependence on collaboration milestones from AbbVie and Gilead for non-dilutive funding
- Potential dilution from Series C warrant exercises
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-218194 |
| Document: xlo-20260512.htm | 0001193125-26-218194 |
| Document: 0001193125-26-218194-index-headers.html | 0001193125-26-218194 |
| Document: 0001193125-26-218194-index.html | 0001193125-26-218194 |
| Document: 0001193125-26-218194.txt | 0001193125-26-218194 |
| 8-K Data (Synthetic) | 0001193125-26-218194 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | Press Release | — | awaiting T+5 | — | — |
Aug 12, 2026 10w ago | 8-K | $9.05 $9.41 | ▲ +3.98% | ▲ +4.42% | $8.16 (−9.81%) |
Aug 12, 2026 10w ago | Press Release | $9.05 $9.41 | ▲ +3.98% | ▲ +4.42% | $8.16 (−9.81%) |
Jun 1, 2026 21w ago | EFFECT | $8.25 $7.70 | ▲ +6.67% | ▲ +3.92% | $8.16 (+1.06%) |
May 27, 2026 21w ago | S-3/A | $8.52 $8.15 | ▼ −4.40% | ▼ −4.35% | $8.16 (−4.20%) |
May 12, 2026 23w ago | 8-K | $7.73 $8.15 | ▲ +5.43% | ▲ +5.36% | $8.16 (+5.60%) |
May 12, 2026 23w ago | Press Release | $7.73 $8.15 | ▲ +5.43% | ▲ +5.36% | $8.16 (+5.60%) |
Apr 17, 2026 27w ago | Press Release | $8.45 $8.18 | ▼ −3.20% | ▼ −4.11% | $8.16 (−3.40%) |
Apr 16, 2026 27w ago | 3 | $8.57 $8.31 | ▼ −3.03% | ▼ −3.59% | $8.16 (−4.75%) |
Apr 16, 2026 27w ago | 8-K | $8.35 $8.47 | ▲ +1.44% | ▲ +0.45% | $8.16 (−2.25%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers